Trial Profile
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Tesnatilimab (Primary) ; Ustekinumab
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms TRIDENT
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
- 27 Sep 2022 Results assessing population pharmacokinetic of Tesnatilimab in Moderately to Severely active Crohns Disease modeling presented at the 2022 American College of Clinical Pharmacology Annual Meeting
- 12 Apr 2022 Status changed from active, no longer recruiting to completed.
- 29 Sep 2020 Planned End Date changed from 1 Sep 2022 to 10 Sep 2022.